Ibogaine has become one of the more closely watched compounds in psychedelic medicine, drawing bipartisan political support, state-funded research dollars in Texas, and a growing body of patient accounts describing sharp reductions in addiction cravings and withdrawal symptoms. It has also become the subject of mounting safety concerns.

A New York Times investigation published in August documented a pattern of adverse events at psychedelic clinics operating outside the U.S., where patients seeking ibogaine and other treatments have died or been seriously harmed. Reporters found inconsistent medical screening, staff distributing medications without regard to a patient’s history, and no central system tracking injuries or deaths across facilities. Because ibogaine is a Schedule I substance in the U.S., it has no legal domestic treatment pathway, leaving patients to travel to clinics in Mexico, Costa Rica, and elsewhere with widely varying oversight standards.

The underlying safety issue is pharmacological, not just procedural: ibogaine is associated with QT interval prolongation, a change in cardiac electrical activity that can trigger fatal arrhythmias, and treatment typically involves a hallucinogenic experience lasting 10 hours or more under medical supervision. Better screening and monitoring can reduce risk at the margins, but they don’t eliminate the molecule’s underlying cardiac liability.

A Different Bet: Replace the Molecule, Not the Protocol

That gap is what Equulus Therapeutics, a small, largely unknown biotech, says it’s trying to close — not by making ibogaine safer to administer, but by developing a different drug entirely.

The company’s lead candidate, EQL-101, is a next-generation compound derived from ibogaine’s pharmacology, engineered with the explicit goal of preserving its effects on craving and withdrawal while avoiding the cardiac risk and extended psychoactive experience associated with the natural alkaloid. Equulus says the aim is a treatment that could eventually be prescribed and monitored within a conventional U.S. clinical framework, rather than requiring patients to seek treatment overseas.

Other efforts to make ibogaine viable as medicine, including Texas’s state-backed research initiative, are focused on the first strategy: refining screening, dosing, and monitoring protocols for the existing molecule. Equulus’s approach, building a distinct chemical entity rather than a safer delivery method, is a different bet on the same underlying problem the Times’ reporting laid out, that ibogaine’s clinical promise has outrun the infrastructure meant to deliver it safely.

Whether that bet pays off will depend on data Equulus has not yet published. But it reflects a broader question the industry is increasingly being forced to confront: whether ibogaine’s future lies in making the drug itself safer to use, or in using what it has revealed about addiction pharmacology to build something safer in its place.